
Anne-Marte Bakken Kran
- Consultant, Department director FHI; MD, PhD
- +47 22 11 85 04
Publications 2025
High-dimensional single-cell phenotyping unveils persistent differences in immune cell profiles between severe and moderate seasonal influenza
16, 1576861
DOI 10.3389/fimmu.2025.1576861, PubMed 40766325
Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study
57, 101416
DOI 10.1016/j.lanepe.2025.101416, PubMed 40823191
Publications 2024
No association between disease severity and respiratory syncytial virus subtypes RSV-A and RSV-B in hospitalized young children in Norway
19 (3), e0298104
DOI 10.1371/journal.pone.0298104, PubMed 38466702
Clinical trial: An open-label, randomised trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B
60 (4), 434-445
DOI 10.1111/apt.18147, PubMed 38970293
Emergence of enterovirus D68 in a Norwegian paediatric population 2012-2022
Frontiers in Virology, 4, 1-7
DOI 10.3389/fviro.2024.1358963, PublikaID 493
Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults
24 (1), 841
DOI 10.1186/s12879-024-09670-w, PubMed 39164637
Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies
21 (1), 120
DOI 10.1186/s12954-024-01023-9, PubMed 38890611
Publications 2023
Convalescent plasma from Norwegian blood donors to treat COVID-19
143 (11)
DOI 10.4045/tidsskr.22.0180, PubMed 37589362
Publications 2022
Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21
27 (13)
DOI 10.2807/1560-7917.ES.2022.27.13.2100376, PubMed 35362405
The burden of hospital-attended influenza in Norwegian children
10, 963274
DOI 10.3389/fped.2022.963274, PubMed 36160779
Risk factors associated with severe disease in respiratory syncytial virus infected children under 5 years of age
10, 1004739
DOI 10.3389/fped.2022.1004739, PubMed 36110112
Corrigendum to 'The burden of respiratory syncytial virus in children under 5 years of age in Norway' [Journal of Infection Volume 84, Issue 2 (2022) Pages 205-215]
86 (4), 420
DOI 10.1016/j.jinf.2022.12.018, PubMed 36572618
Duodenal inflammation in common variable immunodeficiency has altered transcriptional response to viruses
151 (3), 767-777
DOI 10.1016/j.jaci.2022.09.029, PubMed 36220400
COVID-19 convalescent plasma from Norwegian blood donors
142 (9)
DOI 10.4045/tidsskr.22.0057, PubMed 35699539
Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021
16 (6), 1004-1013
DOI 10.1111/irv.13024, PubMed 35770841
Clinical characteristics and outcomes in hospitalized adult influenza patients: an observational study from Norway 2014-2018
54 (5), 367-377
DOI 10.1080/23744235.2021.2022196, PubMed 34983302
Publications 2021
Impact of the Rotavirus Vaccination Program in Norway After Four Years With High Coverage
40 (4), 368-374
DOI 10.1097/INF.0000000000003020, PubMed 33399430
The burden of respiratory syncytial virus in children under 5 years of age in Norway
84 (2), 205-215
DOI 10.1016/j.jinf.2021.12.008, PubMed 34906596
Diagnostic performance of a SARS-CoV-2 rapid antigen test in a large, Norwegian cohort
137, 104789
DOI 10.1016/j.jcv.2021.104789, PubMed 33736946
Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic
16 (2), 204-212
DOI 10.1111/irv.12932, PubMed 34751488
Publications 2020
Field performance of HBsAg rapid diagnostic tests in rural Ethiopia
289, 114061
DOI 10.1016/j.jviromet.2020.114061, PubMed 33388369
Evaluation of eleven rapid tests for detection of antibodies against SARS-CoV-2
58 (9), 1595-1600
DOI 10.1515/cclm-2020-0628, PubMed 32598303
Publications 2019
HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors
17 (1), 4
DOI 10.1186/s12916-018-1241-1, PubMed 30616632
To what extent can clinical characteristics be used to distinguish encephalitis from encephalopathy of other causes? Results from a prospective observational study
19 (1), 80
DOI 10.1186/s12879-018-3570-2, PubMed 30669985
Encephalitis and aseptic meningitis: short-term and long-term outcome, quality of life and neuropsychological functioning
9 (1), 16158
DOI 10.1038/s41598-019-52570-2, PubMed 31695095
Publications 2018
Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort
32 (2), 161-169
DOI 10.1097/QAD.0000000000001689, PubMed 29112061
High neopterin and IP-10 levels in cerebrospinal fluid are associated with neurotoxic tryptophan metabolites in acute central nervous system infections
15 (1), 327
DOI 10.1186/s12974-018-1366-3, PubMed 30470234
Stratification by interferon-γ release assay level predicts risk of incident TB
73 (7), 652-661
DOI 10.1136/thoraxjnl-2017-211147, PubMed 29622693
Publications 2016
A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency
111 (10), 1467-1475
DOI 10.1038/ajg.2016.329, PubMed 27527747
Rapid Bedside Inactivation of Ebola Virus for Safe Nucleic Acid Tests
54 (10), 2521-9
DOI 10.1128/JCM.00346-16, PubMed 27466385
Publications 2015
Primary resistance to integrase strand-transfer inhibitors in Europe
J. Antimicrob. Chemother., 70 (10), 2885-2888
DOI 10.1093/jac/dkv202
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
62 (5), 655-663
DOI 10.1093/cid/civ963, PubMed 26620652
Two cases of acute severe flaccid myelitis associated with enterovirus D68 infection in children, Norway, autumn 2014
20 (10), 21062
DOI 10.2807/1560-7917.es2015.20.10.21062, PubMed 25788251
Publications 2014
High frequency of enterovirus D68 in children hospitalised with respiratory illness in Norway, autumn 2014
9 (2), 59-63
DOI 10.1111/irv.12300, PubMed 25534826
Comparable Cellular Immune Responses in Patients with and without Antiretroviral Treatment after Immunization with HIV-1 P24, P17 and Tat Consensus Peptides (Vacc-5q)
J AIDS Clin Res, 5 (4), 1000294
DOI 10.4172/2155-6113.1000296, PublikaID 217
Publications 2013
Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration
PLoS One, 8 (7), e71174
DOI 10.1371/journal.pone.0071174
Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts
Clin. Infect. Dis., 56 (6), 888-897
DOI 10.1093/cid/cis1000
Publications 2012
Infectious encephalitis: a description of a Norwegian cohort
45 (3), 179-85
DOI 10.3109/00365548.2012.719634, PubMed 23113672
Publications 2011
Hospitalised patients with suspected 2009 H1N1 influenza A in a hospital in Norway, July - December 2009
11, 75
DOI 10.1186/1471-2334-11-75, PubMed 21435254
Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infection
120 (3), 204-9
DOI 10.1111/j.1600-0463.2011.02843.x, PubMed 22339677
Publications 2010
Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides
24 (17), 2609-18
DOI 10.1097/QAD.0b013e32833e502b, PubMed 20935558
Publications 2009
Overestimation of human immunodeficiency virus type 1 load caused by the presence of cells in plasma from plasma preparation tubes
47 (7), 2170-4
DOI 10.1128/JCM.00519-09, PubMed 19420166
Publications 2006
Peptide-based therapeutic immunizations targeting dendritic cells in chronic HIV-1 infection
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 402, 1 b. (flere pag.)
BIBSYS 060843748, ISBN 82-8080-169-3
Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment
20 (6), 813-20
DOI 10.1097/01.aids.0000218544.54586.f1, PubMed 16549964
Publications 2005
Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization
23 (31), 4011-5
DOI 10.1016/j.vaccine.2005.03.010, PubMed 15963359
Publications 2004
HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)
18 (14), 1875-83
DOI 10.1097/00002030-200409240-00003, PubMed 15353973